We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000519:SZSENorth Industries Group Red Arrow Co., Ltd Analysis

Data as of 2026-03-12 - not real-time

CN¥18.97

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

North Industries Group Red Arrow (000519.SZ) trades at CNY 18.97, well above its DCF fair value of roughly CNY 7.8 and carries a forward PE of 33.9 versus an industry average of 29.4, indicating a potentially overvalued pricing level. Technical signals are mixed: the 20‑day SMA (≈19.49) sits above the current price, the 14‑day RSI is neutral at 45, and the MACD histogram is negative, suggesting short‑term bearish momentum, while the overall trend remains neutral. The stock exhibits high 30‑day volatility (≈42%) but an almost zero beta, reflecting limited systematic market risk but elevated idiosyncratic swings. Fundamentals are weak – revenue grew 44.8% YoY, yet gross margin is only 10.2% and the company posted a negative profit margin of –6.2%, with ROE and ROA both negative, and a high debt‑to‑equity ratio of 6.3. Cash holdings (≈CNY 5.23 bn) comfortably exceed total debt (≈CNY 0.65 bn), providing liquidity cushion despite the earnings shortfall. Recent regulatory scrutiny, highlighted by fines and warnings to executives, adds a layer of compliance risk. The stock’s upside potential of about 26% (per the provided upside/downside metric) is offset by its overvaluation and profitability concerns, making the risk‑reward profile tilted toward caution.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 5/10

Key Factors

  • price below 20‑day SMA
  • bearish MACD histogram
  • elevated short‑term volatility

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • strong revenue growth but negative earnings
  • ample cash relative to debt
  • neutral technical trend

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • persistent profitability deficits
  • overvalued relative to DCF and peers
  • regulatory exposure from executive fines

Key Metrics & Analysis

Financial Health

Revenue Growth44.80%
Profit Margin-6.18%
P/E Ratio33.9
ROE-3.63%
ROA-1.79%
Debt/Equity6.30
P/B Ratio2.6
Op. Cash FlowCN¥675.7M
Free Cash FlowCN¥166.3M
Industry P/E29.4

Technical Analysis

TrendNeutral
RSI45.5
SupportCN¥18.12
ResistanceCN¥21.80
MA 20CN¥19.49
MA 50CN¥19.07
MA 200CN¥19.13
MACDBearish
VolumeIncreasing
Fear & Greed Index74.82

Valuation

Fair ValueCN¥7.83
Target PriceCN¥24.00
Upside/Downside26.52%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta-0.00
Volatility41.77%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.